Iboga
A common name for the plant and, depending on context, for preparations made from its root or root bark. It is not a precise description of composition or potency.
Iboga and ibogaine, clarified
Terminology FAQ
A plain-language guide to commonly confused terms: plant and compound, metabolite and preparation, cultural context and legal status.
Start with the distinction
Is iboga the same as ibogaine?
No. Iboga is the name commonly used for Tabernanthe iboga, a shrub native to Central Africa, as well as for plant materials prepared from it. Ibogaine is one psychoactive alkaloid associated with the plant. A general overview of the Tabernanthe iboga plant can help keep the botanical term separate from the chemical one.
For people researching Ibo Mind, the distinction is practical: a phrase such as “iboga” may refer to a whole plant, root bark, an extract, or a tradition, while “ibogaine” ordinarily refers to a specific compound. The broader Ibo Mind evidence and safety overview uses these terms with that distinction in view.
A pared-back vocabulary
Plant material and isolated compound are different descriptions.
Ibogaine
An alkaloid found in iboga. It can be discussed as a molecule, a substance in research, or an isolated preparation; those uses still do not make it synonymous with the whole plant.
Noribogaine
A metabolite, meaning a compound formed as the body processes ibogaine. It is neither a second name for iboga nor a label for root bark.
Root bark
Plant material. It may contain multiple constituents, and its composition can vary. It cannot be equated with a purified single compound.
Metabolites and preparations
What is noribogaine, and can root bark be equated with purified ibogaine?
Noribogaine is a metabolite of ibogaine: it is formed during metabolism. That relationship is why the two terms often appear together in pharmacology discussions, but they are not interchangeable. The National Library of Medicine’s compound record for ibogaine is useful for identifying the molecule separately from plant preparations.
Root bark, by contrast, is botanical material with a variable mixture of compounds. “Purified ibogaine” names an isolated compound. Treating those phrases as equivalents can obscure what is being discussed, including uncertainty about composition. The site’s terminology guide provides a broader plain-language framework for reading these labels.
Context changes the word
Is iboga a psychedelic or a sacrament?
These words answer different questions. “Psychedelic” is a broad label used in discussions of psychoactive effects. “Sacrament” describes a ceremonial or spiritual role within a particular cultural setting. Neither term by itself identifies a preparation, establishes safety, or settles legal status.
Botanical context
“Iboga” may identify a plant or a material derived from that plant.
Cultural context
In some settings, iboga is discussed in relation to Bwiti traditions; the label “sacrament” belongs to that context, not to a universal chemical category.
Pharmacological context
“Psychedelic” is often used broadly, but it should not erase distinctions among plant material, ibogaine, noribogaine, and other constituents.
Frequently confused boundaries
What are the legal and safety distinctions?
Legal categories and safety questions need their own language. A substance’s legal status may differ by jurisdiction and may not map neatly onto a botanical name, a derivative, or an isolated compound. Safety information is not a treatment recommendation.
Does legal status follow one simple rule?
No. Laws vary by country and can distinguish between iboga, ibogaine, preparations, importation, possession, or medical research. In the United States, ibogaine is listed in the DEA’s controlled-substances listing, but that document does not determine the law elsewhere. Check current local rules rather than relying on broad online claims.
Is “addiction cure” accurate language?
No. It is an overstatement that can hide uncertainty and risk. Research interest does not establish a cure, and a term describing possible use should never be read as a guarantee of outcome. For a clearer distinction between information and services, see the site’s explanation of what Ibomind provides.
Why is cardiac risk mentioned so often?
Ibogaine has been associated with potentially serious effects on cardiac rhythm, including QT-interval concerns. The FDA’s discussion of QT-related rhythm risk explains why this kind of cardiac issue is treated seriously in medicine generally; it is not a finding that makes any iboga-related preparation safe.
Further precautions
Clear words are not proof of safety, legality, quality, or benefit.
Keep the limits of evidence visible.
- Evidence about iboga and ibogaine remains limited, context-dependent, and insufficient to support “cure” language.
- Plant material, extracts, and isolated compounds should not be treated as interchangeable; composition and legal classification can differ.
- Known cardiac-risk concerns around ibogaine are serious, and this page does not offer medical guidance or a recommendation to use any substance.
- Terms such as “natural,” “traditional,” “psychedelic,” and “sacrament” do not by themselves establish safety, efficacy, or legality.
Questions about the scope and independence of this resource can be placed in the context of Ibomind’s stated approach. If you need to raise a site question, the available contact route is intended for that purpose.
Continue with the terminology guide